2020
Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19
Park A, Iwasaki A. Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19. Cell Host & Microbe 2020, 27: 870-878. PMID: 32464097, PMCID: PMC7255347, DOI: 10.1016/j.chom.2020.05.008.Peer-Reviewed Original ResearchConceptsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Syndrome coronavirus 2Role of interferonType ICoronavirus disease 2019COVID-19Innate antiviral responseOngoing global threatCoronavirus 2Pathogenic coronavirusesTreatment strategiesDisease 2019Protective effectHuman coronavirusesRecombinant interferonMERS-CoVSARS-CoVAntiviral responseInterferonAntiviral therapeuticsCombat COVID-19Interferon inductionGlobal pandemicContributions of maternal and fetal antiviral immunity in congenital disease
Yockey LJ, Lucas C, Iwasaki A. Contributions of maternal and fetal antiviral immunity in congenital disease. Science 2020, 368: 608-612. PMID: 32381717, DOI: 10.1126/science.aaz1960.Peer-Reviewed Original ResearchConceptsViral infectionCongenital diseaseDirect viral toxicityMaternal immune responseMaternal immune activationFetal developmental defectsFuture treatment strategiesImmune defense mechanismsPregnancy outcomesFetal demiseImmune activationUncontrolled inflammationMaternal healthChronic infectionTreatment strategiesImmune responseAntiviral immunityRange of syndromesFetal developmentTissue damagePathological effectsInfectionViral toxicityDevastating consequencesPregnancy
2017
β-hydroxybutyrate deactivates neutrophil NLRP3 inflammasome to relieve gout flares
Goldberg E, Asher J, Molony R, Shaw A, Zeiss C, Wang C, Morozova-Roche L, Herzog R, Iwasaki A, Dixit V. β-hydroxybutyrate deactivates neutrophil NLRP3 inflammasome to relieve gout flares. The Journal Of Immunology 2017, 198: 206.18-206.18. DOI: 10.4049/jimmunol.198.supp.206.18.Peer-Reviewed Original ResearchKetogenic dietGouty flaresNLRP3 inflammasomeSmall clinical trialsCurrent treatment strategiesMajor risk factorNLRP3-dependent ILAnti-inflammatory moleculesIL-1R antagonistAlternate metabolic fuelsGout flaresJoint destructionGout patientsIL-1βIntense painRisk factorsClinical trialsInflammatory neutrophilsTreatment strategiesImmune responseUrate crystalsBacterial infectionsNeutrophilsGoutNLRP3